Shopping Cart
Remove All
Your shopping cart is currently empty
Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that inhibits PD-1 and CTLA-4 to enhance T-cell responses, currently being investigated for metastatic castration-resistant prostate cancer (mCRPC) [1] [2] [3].
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 5 mg | Inquiry | Inquiry | Inquiry |
| Description | Lorigerlimab (MGD019) is a bispecific IgG4 dual-affinity re-targeting (DART) antibody that inhibits PD-1 and CTLA-4 to enhance T-cell responses, currently being investigated for metastatic castration-resistant prostate cancer (mCRPC) [1] [2] [3]. |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Endotoxin | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Target | PD-1/CTLA-4 |
| Cas No. | 2416595-46-3 |
| Storage | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.